The main purposes of this study is to determine the following in participants with mild
coronavirus disease 2019 (COVID-19):
- Safety of a single dose of NT-I7
- The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.
Phase:
Phase 1
Details
Lead Sponsor:
NeoImmuneTech
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) University of Nebraska